While larger companies have proved that vertical integration and in vitro diagnostic business models work, a defined development path for the success of smaller, cash-strapped diagnostic companies has yet to emerge. This panel will discuss how smaller biotechnology companies can build a diagnostic business model that appeals to investors and explore the challenges and opportunities within the diagnostic space.



Objectives:

Evaluate the success of vertical integration and in vitro diagnostic business models, and compare the two pathways to market.

Discuss current challenges that entrants into the diagnostic arena are facing in a competitive and young investment space.

Provide tips and suggestions for smaller diagnostic companies to facilitate the business model development with the most promising path to market opportunities.